Figure 2.

Kaplan Meier curves illustrating an overall survival advantage for patients with triple negative metastastic breast cancer treated with the PARP inhibitor, BSI-201 (BiPAR Sciences/Sanofi Aventis) plus carboplatin/gemcitabine chemotherapy compared to chemotherapy alone (12.2 versus 7.2 months, p = 0.005)(36).